EICHOR
● Completed
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus · Chronic Kidney Disease · Sponsor: Bayer
About this study
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD. Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine. In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the participants' kidney function compared to either treatment alone. For this, the level of protein in the urine will be measured. The investigators also want to know how safe the combination is compared to either treatment alone. Depending on the treatment group, the participants will either take the combination of finerenone and empagliflozin, or finerenone together with a placebo, or empagliflozin together with a placebo, once a day as tablets by mouth. A placebo looks like a treatment but does not have any medicine in it. Importantly, the participants will also continue to take their other current medicine for CKD and T2D. The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, participants will visit the study site 7 times. The study team will: * collect blood and urine samples * check the participants' vital signs * do a physical examination including height and weight * check the participants' heart health by…
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (173)
| Southwest Kidney Institute, PLC - Suprise | Surprise, Arizona, United States | — |
| Academic Medical Research Institute | Los Angeles, California, United States | — |
| Dignity Health Northridge Hospital Medical Center - Nephrology | Northridge, California, United States | — |
| Olive View - UCLA Medical Center | Sylmar, California, United States | — |
| Touro University California - Metabolic Research Center | Vallejo, California, United States | — |
| Florida Kidney Physicians - Delray Beach Nephrology | Delray Beach, Florida, United States | — |
| West Orange Endocrinology & Clinical Research | Ocoee, Florida, United States | — |
| Innovative Research Institute | Port Charlotte, Florida, United States | — |
| Metabolic Research Institute, Inc. | West Palm Beach, Florida, United States | — |
| Grady Memorial Hospital - Endocrinology | Atlanta, Georgia, United States | — |
| Southeast Kidney Associates - East Point | East Point, Georgia, United States | — |
| Velocity Clinical Research - Savannah | Savannah, Georgia, United States | — |
+ 161 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05254002